Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has suspended the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program evaluating the investigational compound Tanezumab, a monoclonal antibody against nerve growth factor, at the request of FDA.
Subscribe to our email newsletter
Reportedly, investigation of the compound continues in some areas of high unmet medical need, including cancer pain.
Considering of reports of adverse events in osteoarthritis patients taking Tanezumab, and the agency’s concerns regarding the potential for such events in other patient populations in which the compound is being studied, the FDA has requested for the hault of the trial.
Previously Pfizer has suspended Tanezumab studies in patients with osteoarthritis in a June 2010.
Pfizer is expected to continue to work with the FDA to reach a common understanding about the appropriate scope of continued clinical investigation of Tanezumab.